Ozagrel Sodium for Injection

This product is a thromboxane synthetase inhibitor that can inhibit the production of TXA2, thus having the effects of anti-platelet aggregation and vasodilation. Animal experiments have shown that intravenous administration can reduce plasma TXB2 levels and the Keto-PGF12/TXB2 ratio, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by the middle cerebral artery in rats.

Ozagrel sodium.

It is suitable for the treatment of acute thrombotic cerebral infarction and movement disorders associated with cerebral infarction.

Adults: 40mg~80mg (2~4 vials) at a time, 1~2 times a day, dissolved in 500ml of normal saline or 5% glucose solution, continuous intravenous drip, 2 weeks as a course of treatment.

Gastrointestinal reactions and allergic reactions, such as nausea, vomiting, urticaria, rash, etc., are relieved after appropriate treatment. A few cases may experience increased GPT and BUN, intracranial, gastrointestinal, subcutaneous bleeding, and thrombocytopenia.

The following conditions are contraindicated: 1. Patients with hemorrhagic cerebral infarction, or deep coma due to large-area cerebral infarction; 2. Patients with severe heart, lung, liver, and kidney dysfunction, such as severe arrhythmia and myocardial infarction; 3. Patients with blood diseases or bleeding tendency; 4. Patients with severe hypertension, with systolic blood pressure exceeding 26.6kpa (i.e., more than 200 mmHg); 5. Patients who are allergic to this product.

Avoid mixing with calcium-containing infusions.

Keep away from light and store in a sealed container.

80mg (calculated as ozagrel sodium)

Xi'an Yuanda Detian Pharmaceutical Co., Ltd.

• Founded in:

  2002-12-20

• Address:

  No. 9, Chuangxin Road, New Industrial Park, Xi'an High-tech Industrial Development Zone

• Tax NO.:

  91610131742830863Y

• Registered Funds:

  82.451 million yuan

• Website:

  Log in to view

• Email:

  Log in to view